- Indications for use
- Mode of application
- Side effects
- Interaction with other drugs
- Storage conditions
- Release form
A drug Valsartan reduces myocardial hypertrophy against arterial hypertension. After a single dose, the effect develops after 2 hours, lasts up to a day. Persistent therapeutic efficacy is observed after 3 weeks of administration. When discontinuation of withdrawal is not observed. In patients with CHF, the drug eliminates hyperstimulation of the RAAS, reduces swelling, and prevents pathological cell proliferation. With drug therapy, preload is reduced and cardiac output is increased. When combined with captopril, Valsartan can reduce the risk of post-infarction complications.
Indications for use
A drug Valsartan used in primary hypertension, acute myocardial infarction, secondary hypertension, congestive heart failure.
Mode of application
Pills Valsartan take inside. Tablets are not recommended to chew. In hypertension, the standard daily dosage corresponds to 80 mg of valsartan. Increasing the dosage is carried out only with insufficient therapeutic efficacy. The maximum daily dose is 640 mg. To achieve the required dose, the increase in daily dosing is carried out gradually. After a heart attack, 40 mg / day is prescribed during the initial hours, then a gradual increase is made up to 320 mg / day over 3 months. When there is hypotension in a patient, dosage reduction is carried out.
Drug use Valsartan may be accompanied by side effects: neutropenia, asthenic conditions, postural dizziness, changes in libido, angioedema, viral infections, acute renal failure, loss of consciousness, pruritus, myalgia, insomnia, diarrhea, hyperkalemia, insomnia, arthralgia, thrombocytopenia, sinusitis, hypotension , hypersensitivity reactions, vertigo, impaired kidney function, cough, pharyngitis, back pain, anemia, heart failure, skin rash, change hematocrit, serum sickness, nausea, vasculitis, orthostatic hypotension, pain in the epigastric, rhinitis, edema.
A drug Valsartan It is contraindicated to take when hypersensitivity to valsartan, auxiliary components of tablets, pregnancy, indications in pediatrics, severe violations of the liver, lactation. With caution, Valsartan tablets are prescribed for renal artery stenosis, dehydration, hypo-sodium diet, obstruction of the biliary tract, renal failure (severe).
Due to the danger to the fetus Valsartan not assigned to pregnant women.
Interaction with other drugs
With the simultaneous use of diuretics in high doses may develop arterial hypotension. With simultaneous use of potassium-sparing diuretics, heparin, dietary supplements or salt substitutes containing potassium, hyperkalemia may develop. If used simultaneously with indomethacin, a decrease in the antihypertensive effect of valsartan is possible. carbonate described the case of lithium intoxication.
Overdose therapeutic doses of the drug Valsartan accompanied by hypotension, shock, collapse. Therapeutic assistance is to clean the digestive tract, normalize the BCC, eliminate symptoms. Hemodialysis for the elimination of valsartan is not effective.
Pill storage temperature Valsartan – up to 30 degrees Celsius. Validity of the drug for use – 3 years.
A drug Valsartan Available in tablets of three dosages. Packaging for each dosage: – 7 tab. / Packaging; – 10 tab. / Packaging; – 14 tab. / Packaging; – 20 tab. / Packaging; – 28 tab. / Packaging; – 30 tab. / Packaging; – 40 tab. ./packaging; – 50 tab. / packing; – 56 tab. / packing; – 100 tab. / packing.
1 tablet Valsartan 40 contains valsartan 40 mg. Auxiliary components: magnesium stearate, MCC, croscaramellose sodium, aerosil, opadry pink dye .1 tablet Valsartan 80 contains valsartan 80 mg. Auxiliary components: magnesium stearate, MCC, croscaramellose sodium, aerosil, opadry pink dye .1 tablet Valsartan 160 contains valsartan 160 mg. Auxiliary components: magnesium stearate, MCC, croscaramellose sodium, aerosil, dye “Opadra pink”.